Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-EGFR/anti-HER3 bispecific antibody-drug conjugate IBI3005

An antibody-drug conjugate (ADC) composed of a bispecific antibody directed against the tumor associated antigens (TAAs) human epidermal growth factor receptor (EGFR; HER1; ErbB1), and human epidermal growth factor receptor 3 (HER3; ErbB3) conjugated to a camptothecin derivative, with potential antineoplastic activity. Upon administration, anti-EGFR/anti-HER3 bispecific ADC IBI3005 targets and simultaneously binds to EGFR and HER3 expressed on tumor cells. This blocks EGFR activation by ligands and EGFR-mediated signaling. Upon binding and internalization, the camptothecin derivative is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis in EGFR- and HER3-expressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. HER3, a member of the EGFR family of receptor tyrosine kinases, is frequently overexpressed in tumors.
Synonym:ADC IBI3005
anti-EGFR/anti-HER3 ADC IBI3005
anti-EGFR/anti-HER3 bispecific ADC IBI3005
anti-EGFR/HER3 bispecific ADC IBI3005
EGFR x HER3 bispecific ADC IBI3005
Code name:IBI 3005
IBI-3005
IBI3005
Search NCI's Drug Dictionary